

Draft Guidance on Levofloxacin

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Levofloxacin

Form/Route: Tablet/Oral

Recommended Studies: 2 Options: BCS or In-Vivo Studies

I. BCS Waiver option:

It may be possible to request a waiver of in-vivo testing for all the strengths of this product provided that the appropriate documentation regarding high solubility, high permeability and rapid dissolution as detailed in the Guidance for Industry: *Waiver of In-Vivo Bioavailability and Bioequivalence for Immediate – Release Solid Oral Dosage Forms Based on the Biopharmaceutics Classification System* is submitted in the application. You may use information contained in the approved labeling of the reference product. Peer reviewed articles may not contain the necessary details of the testing for the Agency to make a judgment regarding the quality of the studies. A decision regarding the acceptability of the waiver request can only be made upon review of the data submitted in the application.

II. In-vivo option:

1. Type of study: Fasting
Design: Single-dose, two way crossover in-vivo
Strength: 750 mg
Subjects: Healthy males and nonpregnant females, general population
Additional Comments: Alternatively, BCS Class 1 Waiver Request
2. Type of study: Fed
Design: Single-dose, two way crossover in-vivo
Strength: 750 mg
Subjects: Healthy males and nonpregnant females, general population
Additional Comments: Please see comment above

Analytes to measure (in appropriate biological fluid): Levofloxacin in plasma, using an achiral assay

Bioequivalence based on (90% CI): Levofloxacin

Waiver request of in-vivo testing: 250 mg and 500 mg based on (i) acceptable bioequivalence studies on the 750 mg strength, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity in the formulations across all strengths.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.